Endo Pharmaceuticals

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Packaging

Endo recalls one lot of Edex

Endo Pharmaceuticals has recalled one lot of Edex (alprostadil for injection) 10mcg to the consumer level, due to lack of sterility assurance

New Chief Medical Officer at Endo

Craig Paterson takes responsibility for global clinical development strategies at the company
Finance

Endo buys portfolio of branded and generic products

Acquisition supports continued growth in South Africa and adds some 60 on-market products and nearly 70 R&D pipeline programmes
Finance

Endo to purchase Par Pharmaceutical for US$8.05bn

Expanding generics business, product portfolio, pipeline and manufacturing capabilities
Finance

Valeant increases offer for Salix to US$15.8bn in cash

Endo withdraws its offer for the US manufacturer of gastrointestinal drugs
Finance

Endo submits offer to purchase Salix Pharmaceuticals for about US$15.7bn

Higher bid than Valeant's offer of $14.5bn in February
Pharmaceutical

Endo announces changes to senior management team

To accelerate growth both organically and through corporate development activities
Subscribe now